Loading
companiesCompany
Omega Funds
A Boston and Geneva venture firm that invests in medicines across oncology, immunology and rare disease. Its impact page lists cancer products it helped bring to patients, including the lung cancer drug Ibtrozi and the colorectal screening test Epi proColon.
Overview
Omega Funds has offices at 888 Boylston Street, Boston, and Place du Molard 7, Geneva, and invests through numbered funds (Omega Fund IV to VIII). Its site says it backs 'exceptional founders and entrepreneurs and impactful products and platforms' across oncology, immunology, rare diseases and precision medicine, and that it has 'helped bring 55 products to patients'. The firm invests from company creation through crossover rounds in the United States and Europe. Its impact page lists products from portfolio companies, including Ibtrozi (taletrectinib) for ROS1-positive non-small cell lung cancer, Imlygic (the first oncolytic viral therapy), Epi proColon (the first blood test for colorectal cancer screening) and Epi proLung (an mSHOX2 assay for suspected lung cancer).
Headquarters
Boston, MA, US
Scorecard
All companies#161of 1244 companies, score 36
- approved products +12
- targets +2
- modalities +4
- regions +6
- registry trials +12
2 approved, 0 in phase 3, 0 earlier, 1 targets, 37 registry studies. Formula on the scorecards page.
Type
Website
Portfolio (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Callio Therapeutics Seattle, WA, US | Startup | biotech | HER2-positive breast cancer | Series A 2025, $187M |
| Photys Therapeutics Boston, MA, US | Startup | biotech | Series A 2022, $75M |
ApprovedSmall-molecule ROS1 TKI (next generation, CNS-penetrant)
Taletrectinib · Ibtrozi
A ROS1 lung-cancer pill approved in 2025 that works in the brain and after crizotinib, with fewer dizziness-type side effects than repotrectinib.
ApprovedOncolytic virus (HSV-1)
Talimogene laherparepvec · Imlygic
Talimogene laherparepvec (T-VEC, Imlygic) was the first approved oncolytic virus (2015), injected into melanoma skin lesions.
Notes
top- Founding year not stated on the site and there is no Wikipedia article; omitted. The impact page lists products rather than company names, so portfolio examples are given by product.
Similar pages
- CompanyLongwood Fund
Shares Photys Therapeutics and the tag vc.
- CompanyMPM BioImpact
Shares Photys Therapeutics and the tag vc.
- CompanyNovo Holdings
Shares Callio Therapeutics and the tag vc.
- CompanyJeito Capital
Shares Callio Therapeutics and the tag vc.
- CompanyFrazier Life Sciences
Shares Callio Therapeutics and the tag vc.
drugs
ApprovedSmall-molecule ROS1 TKI (next generation, CNS-penetrant)
Taletrectinib · Ibtrozi
ApprovedOncolytic virus (HSV-1)
Talimogene laherparepvec · Imlygic